–AD109 Achieved the Primary Endpoint of Reduced Nighttime Airway Obstruction –AD109 Significantly Improved Daytime Impairment Caused by OSA –AD109 Was Well-Tolerated CAMBRIDGE, Mass. October 17, 2022 – Apnimed, a clinical-stage pharmaceutical company...
CAMBRIDGE, Mass October 12, 2022 – Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies to treat obstructive sleep apnea (OSA) and related disorders, including its lead candidate AD109, today announced that company...
CAMBRIDGE, Mass. July 6, 2021 – Apnimed, a clinical-stage pharmaceutical company focused on developing oral medicines to treat Obstructive Sleep Apnea (OSA) and related disorders, today announced that the Company’s management team will participate in the Ladenburg...